Spotlight On… Medidata buys out Intelemage; Pharm-Olam appoints new exec; and more…

large can lights shining down

The New York, cloud-based clinical research solutions team Medidata ($MDSO) has acquired the Cincinnati, OH-headquartered Intelemage as it looks to expand its medical imaging services. Medidata will integrate Intelemage's technology into its Clinical Cloud program, offering customers what it calls "an end-to-end solution to capture, manage and analyze medical imaging data." Founded in 2007, Intelemage uses medical image file sharing in clinical trials as well as for hospitals, doctors, life science companies, research institutions and core labs. The company also provides tools for medical imaging data capture and workflow management. This follows a spate of deals for Medidata that includes tie-ups with Apple's ($AAPL) ResearchKit and broadening its geographical reach with a recent collaboration in South Korea. Financial details of the Intelemage deal were not disclosed. Release

> Houston, TX-based CRO Pharm-Olam International has appointed Tricia Bland to its management team as its new executive director of strategic projects. Release

> The EMA has said it will review a number of medicines for which studies have been conducted at the Alkem Laboratories site in Taloja, India, where the company tests the bioequivalence of its generics. This follows a recent GCP inspection of the site that raised concerns regarding study data used to support the drug applications of some medicines in the EU. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.